Immortis

Immortis is a London-based biotechnology company focused on developing next-generation cancer immunotherapies. As a spin-out from King's College London, the company leverages a proprietary platform to engineer "off-the-shelf" gamma-delta T-cell therapies designed for enhanced persistence and efficacy against solid tumors. The company's approach addresses the limitations of current CAR-T therapies by improving the fitness and longevity of engineered cells within the immunosuppressive tumor microenvironment. Founded by pioneers in the field of cell therapy, Immortis aims to provide scalable and potent treatments for hard-to-treat cancers.